Answers are grounded in this paper and cite their sources.
Retrospective analysis shows meaningful haematological responses with bortezomib regimens in late-stage cardiac AL amyloidosis, suggesting viable alternatives to traditional therapy.
Cardiac light chain (AL) amyloidosis is a condition with a very poor prognosis. We report a retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and dexamethasone in late-stage cardiac AL amyloidosis. The primary end points were overall survival and haematological response. Both regimens provided meaningful responses in this difficult to treat patient group.
No takes yet. Share an insight, caveat, or question.
Brennan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: